Diffuse ground-glass opacities in a patient with Hodgkin lymphoma and progressive respiratory failure

Drug-induced Lung Disease in the Oncology Patient: From Cytotoxic Agents to Immunotherapy

Drug-induced lung disease is commonly encountered, especially in the oncology setting. Diagnosis is challenging because clinical and radiologic findings are nonspecific, often overlapping with other lung pathologies in these patients due to underlying neoplasia, infection, or other treatment effects such as radiotherapy. Furthermore, oncology patients often receive multiple antineoplastic agents concurrently, and virtually every agent has an association with lung injury. In this article, we will review a variety of antineoplastic agents that are associated with drug-induced injury and discuss incidence, their typical timing of onset, and imaging features.

Medication-induced Pulmonary Injury: A Scenario- and Pattern-based Approach to a Perplexing Problem

Medication-induced pulmonary injury (MIPI) is a complex medical condition that has become increasingly common yet remains stubbornly difficult to diagnose. Diagnosis can be aided by combining knowledge of the most common imaging patterns caused by MIPI with awareness of which medications a patient may be exposed to in specific clinical settings. The authors describe six imaging patterns commonly associated with MIPI: sarcoidosis-like, diffuse ground-glass opacities, organizing pneumonia, centrilobular ground-glass nodules, linear-septal, and fibrotic. Subsequently, the occurrence of these patterns is discussed in the context of five different clinical scenarios and the medications and medication classes typically used in those scenarios. These scenarios and medication classes include the rheumatology or gastrointestinal clinic (disease-modifying antirheumatic agents), cardiology clinic (antiarrhythmics), hematology clinic (cytotoxic agents, tyrosine kinase inhibitors, retinoids), oncology clinic (immune modulators, tyrosine kinase inhibitors, monoclonal antibodies), and inpatient service (antibiotics, blood products). Additionally, the article draws comparisons between the appearance of MIPI and the alternative causes of lung disease typically seen in those clinical scenarios (eg, connective tissue disease-related interstitial lung disease in the rheumatology clinic and hydrostatic pulmonary edema in the cardiology clinic). Familiarity with the most common imaging patterns associated with frequently administered medications can help insert MIPI into the differential diagnosis of acquired lung disease in these scenarios. However, confident diagnosis is often thwarted by absence of specific diagnostic tests for MIPI. Instead, a working diagnosis typically relies on multidisciplinary consensus. ^©RSNA, 2021.

Benign features of infection-related tumor-like lesions of the lung: A retrospective imaging review study

INTRODUCTION

Differentiation of benign and malignant pulmonary tumor-like lesions is challenging but increasingly important. We evaluate the most common imaging features in benign lesions based on the frequency of their appearance and compare with corresponding frequencies in malignant tumors from literature.

METHODS

Retrospective imaging review study in one center between 1 January 2012 and 30 June 2014. We reviewed the data from 2466 pathological examinations of lung specimens collected from the hospital. We excluded malignant or non-tumor-like lesions and identified 133 infection-related lesions for imaging review. The frequency of 11 benign imaging features was evaluated in the selected infection-related tumor-like pulmonary lesions and was compared with corresponding frequency in malignant tumors.

RESULTS

Most of the evaluated lesions were seen to have one to four benign features. The two most common benign features are marginal ground glass or infiltrates (62.4%), followed by pleura-based wedge shape (50.4%). Features with significantly higher frequency in benign infection-related lung lesions than malignancy are calcification or hyperdensity, pleura-based wedge shape, adjacent clustered small nodules, and strongly or poorly enhanced soft tissue part.

CONCLUSIONS

Infection-related lung lesions usually have one to four benign features and the common features with significantly higher frequency than malignant condition are pleura-based wedge shape, calcification or hyperdensity, adjacent clustered small nodules, and strongly or poorly enhanced soft tissue part.

Pleuropulmonary Changes Induced by Drugs in Patients with Hematologic Diseases

Patients with hematologic diseases who are being treated with therapy drugs, or receive radiation therapy or blood transfusions may develop a host of potentially fatal infectious and noninfectious pulmonary complications [1]. The increased complexity of multimodality and high-dose treatment regimens with the intended benefit of augmented antineoplastic efficacy and prolonged disease-free survival, the use of a panel of novel drugs to treat malignant and nonmalignant hematologic conditions (e.g., azacytidine, bortezomib, cladribine, dasatinib, fludarabine, imatinib, lenalidomide, rituximab, and thalidomide), total body irradiation (TBI) and hematopietic stem cell transplantation (HSCT) have increased the incidence of severe sometimes life-threatening pulmonary complications.